Tag: Mcrpc

In July 2023, the U.S. Food and Drug Administration (FDA) granted Ambrx's ARX517 **fast track designation** for metastatic castration-resistant prostate cancer (mCRPC) that has progressed on prior therapy. This status is designed to accelerate the development and review of therapies for serious conditions with unmet medical needs, bringing promising treatments to patients more rapidly.

Xaluritamig (AMG 509) is an investigational immunotherapy showing encouraging antitumor activity in patients with heavily pre-treated metastatic castration-resistant prostate cancer (mCRPC) [1.2.1, 1.6.9]. A key aspect of its clinical profile is its pharmacokinetics, so **what is the half life of Xaluritamig?**

In a Phase 1 study of 97 patients with metastatic castration-resistant prostate cancer, 49% experienced a significant drop in prostate-specific antigen levels after treatment with xaluritamig [1.2.3]. So, **what is amg 509** and how does this promising immunotherapy work?

In early 2025, clinical trial data showed that Mevrometostat combined with enzalutamide reduced the risk of disease progression or death by 49% in some prostate cancer patients. **What is Mevrometostat?** It is an investigational EZH2 inhibitor being developed by Pfizer for advanced prostate cancer.

In a clinical study published in *Cancer Discovery*, 49% of heavily pretreated patients with metastatic castration-resistant prostate cancer experienced a significant reduction in prostate-specific antigen (PSA) levels with the experimental immunotherapy Xaluritamig. This article explores this promising new treatment strategy and its role in oncology.